KR20130030907A - Composition comprising extracts of panax ginseng and crataegis fructus for improving skin beauty - Google Patents

Abstract

The present invention relates to a composition for improving skin care comprising a mixture of ginseng and hawthorn extract in a certain amount by weight, the composition is reduced skin wrinkles, increased skin elasticity, reduced pore size, lighter skin tone, improved pigmentation While showing an excellent effect on the back, it is safe for the human body and can be safely applied to food, medicine and cosmetic composition for improving skin care.

Description

Composition comprising extracts of Panax ginseng and Crataegis fructus for improving skin beauty} including ginseng (Ｐａｎａｘ gｉｎｓｅｎｇ) and sansa (Ｃｒａｔａｅｇｉｓ ｆｒｕｃｔｕｓ) extract

The present invention relates to a composition for improving skin care, comprising a mixture of ginseng and hawthorn extract in a certain amount by weight.

Ginseng (Panax ginseng CA Meyer: Ginseng radix) is one of the most important herbal medicines used mainly in Giheo. It is included in many herbal medicines in Korea, including China, and is used for fatigue recovery, physical strength enhancement, digestive system and nervous system. , Metabolic system, circulatory system, etc., has been used alone or as a prescription medicinal herb (Nam Ki-yeol, the latest Korean ginseng (ingredient and efficacy), 1996). Ginseng's medicinal effect has been researched mainly on saponins, and pharmacological effects on the central nervous system, various stresses, antidiabetic and cardiovascular disorders have been revealed (Benishin CG et al., Effects of Ginsenoside Rb1 on Central Cholinergic Metabolism (1991), Elma ZT et al., Effect of ginsenoside Rg 1 on insulin binding in mice liver and brain membrane (1991), Kang SY et al., Dietary ginsenosides improve endothelium-dependent relaxation in the thoracic aorta of hypercholesterolemic rabbit ( 1995)).

However, in addition to saponins, polyacetylene, a non-saponin-based component of ginseng, has been found to inhibit cancer cell proliferation. Therefore, studies on the physiological activities of active ingredients other than saponins have been conducted (Hwang WI et al., Comparative Study on the Cytotoxic Activities of Red Ginseng of Korea and China, 10: 27-35, 1996).

Based on such herbal efficacy, various experimental and clinical efficacy studies that have been conducted so far have suggested various effects of ginseng. In addition, through active ingredient research, ginsenosides (ginsenosides), which are the main medicinal ingredients of ginseng, include over 30 kinds of ginsenosides (ginsenosides), and non-saponin-based bioactive substances such as polyacetylenes, phenolic compounds, and acidic polysaccharides. , Peptides, alkaloids, amino acid derivatives have been found. Other ingredients of ginseng include volatile oil, sugar, starch, pectin, and minerals. Therefore, based on the history and scientific history of ginseng, interest in ginseng as a tonic or health food and alternative medicine has increased in recent years as well as in the East (Smith M et al., Counseling cancer patients about herbal medicine, 1999).

The fruit of the hawthorn (Crataegus pinnatifida Bunge) is called hawthorn (Crataegis fructus), and the mature fruit of the hawthorn is collected and dried. Book, Seoul: Hyangmunsa, 1979). Pharmacological components of mountain lions include ursolic acid, quercetin, crataegolic acid, tartaric acid, hyperoxide, and vitexin-4-rhamnoside. rhamnoside, citric acid, caffeic acid, choline, ascorbic acid (0.089%), carbohydrates (22%), protein (0.7%), lipids (0.2%), Lipase (lipase, etc.), Korean Society of Pharmaceutical Botanicals, New and Pharmaceutical Botany, Hakchangsa, 1998

Among them, phenolic compounds in herbal medicines have been reported as representative substances with antioxidant activity. The antioxidant activity of the hawthorn extract showed that the antioxidant effect of the hawthorn was superior to the synthetic antioxidant. The phenolic component of the hawthorn was the free phenolic acid of the hawthorn from caffeine, protocatechuic acid and fatigue. Caffeic acid, phloroglucinol, and insoluble phenolic acids were identified as pyrogallol, soluble ester type phenolic acid, and protocatechuic acid and phloroglucinol were found to be the main antioxidants of acid extracts. Et al., Isolation and Identification of Sansa Antioxidant Substances, J. Korean Agric. Chem. Soc, 1993). Until now, most of the studies on hawthorn have been conducted on pharmacological and active ingredients, but the physiological function of hawthorn and the cosmetics industry have not been studied. Therefore, the expected effect of industrial application is very high.

The phenomenon of 'well-being', which greatly affects modern society, implies not only the primary meaning of eating well and living well but also the meaning of 'body's health is expressed by the beauty of skin'. This phenomenon is most common in the field of skin beauty, and skin beauty now needs a complex function and a scientific approach beyond fragmentary efficacy (Kim Eun-young, Journal of the Korean Society of Skin Aesthetics, 2005).

Skin aging can be divided into two types. One is intrinsic aging, which is an aging phenomenon that is inevitable as time goes by. The second is photoaging, which refers to the aging phenomenon observed on the skin of the face, back of the hand, back of the neck, etc., which has been exposed to sunlight for a long time, and is the result of the combination of endogenous aging and the effects of UV rays. Sci Nutr, 2010).

The pores are distributed throughout the facial skin, but the nose and cheek areas can be identified with the naked eye, and the appearance of the pores varies depending on the endogenous and exogenous factors such as sex, genetics, aging, acne and chronic UV exposure. The pores are widened because the sebum is excessively secreted or skin aging begins, and as the collagen fibers and elastic fibers supporting the wall of the pores degenerate and decrease, the skin elasticity is lost and drooped. Society, 2010).

It is known that the cause of skin aging is that matrix proteins such as collagen and elastic fibers are damaged and the amount of collagen in the skin is insufficient, and elastic fibers are denatured. In addition, it is known that collagen synthesis is reduced through various signaling pathways and the expression of matrix metalloproteinases (MMPs), which are enzymes of extracellular matrix proteins, including collagen is increased during skin aging. As collagen is recognized as a major factor related to skin aging, the synthesis and inhibition of collagen synthesis have become important indicators related to skin aging and skin beauty (Nam Kim, Korea Ginseng Society, 2007).

Melanin is reported to be biosynthesized mainly by the action of tyrosinase. Tyrosinase is an enzyme that binds to copper and is widely distributed in animals, plants, microorganisms, and humans, and promotes aerobic oxidation in phenolic compounds such as monohydroxy or dihydroxy phenylalanine (DOPA), Melanocytes are deposited on heavily exposed skin, causing aging or damage to the skin.

The biosynthetic mechanism of melanin has recently been intensively studied in connection with skin cancer, and various melanin-producing inhibitors have been developed from this, and skin whitening agents or foods that prevent and improve skin disease treatment drugs in the pharmaceutical industry, blemishes and freckles in the cosmetic industry, It is applied as a browning agent in the pharmaceutical and cosmetics industries.

Until now, research on melanogenesis inhibitors has been mainly focused on developing tyrosinase inhibitors, and representative tyrosinase inhibitors include chelating agents for copper ions at the tyrosinase active site, reducing agents such as ascorbic acid for reducing quinones to phenols, and Bisulfites preparations that denature tyrosinase itself. For example, as melanin biosynthesis inhibitors, substances having inhibitory activity against tyrosinase such as hydroquinone, ascorbic acid or derivatives thereof, kojic acid, glutathione, arbutin and the like are known. . However, hydroquinone has a problem that the use of skin is very strong because of irritation, and ascorbic acid is easily oxidized, such as discoloration and discoloration of the formulation. In addition, kojic acid is unstable in solution, so the stability of the formulation is low and there is a problem of carcinogenicity for the development of thyroid cancer. In the case of arbutin, its activity is not high, and thiol-based compounds such as glutathione and cysteine not only have a characteristic unpleasant odor, but also have problems with transdermal absorption, and glycosides and derivatives have high polarity, making it difficult to blend into cosmetic raw materials. there is a problem.

Thus, in order to solve the problems such as the whitening material, research to find a whitening active ingredient in natural products is actively being conducted.

-

Nam Ki-Yeol, Latest Korean Ginseng (Ingredients and Effects), 1996 Benishin CG et al., Effects of Ginsenoside Rb1 on Central Cholinergic Metabolism (1991) Elma ZT et al., Effect of ginsenoside Rg 1 on insulin binding in mice liver and brain membrane (1991) Kang SY et al., Dietary ginsenosides improve endothelium-dependent relaxation in the thoracic aorta of hypercholesterolemic rabbit (1995) Hwang WI et al., Comparative Study on the Cytotoxic Activities of Red Ginseng of Korea and China, 10: 27-35, 1996 Smith M et al., Counseling cancer patients about herbal medicine, 1999 Lee Chang-bok, Korea Plant Book, Seoul: Hyangmunsa, 1979 Korean Society of Pharmaceutical Botanical Sciences, New and Pharmaceutical Botanical Sciences, Hakchangsa, 1998 Jung Sook Kim et al., Separation and Identification of Sansa Antioxidant Substances, J.Korean Agric. Chem. Soc, 1993 Eun-Young Kim, The Korean Society of Skin Beauty, 2005 Park Geum-joo, J Korean Soc Food Sci Nutr, 2010 Jik Seok Han, The Korean Aesthetic Society of Korea, 2010 Kim Nam-Ie, Korea Ginseng Society, 2007

An object of the present invention to provide a composition for improving skin beauty having an excellent skin care improvement effect.

Therefore, the present inventors searched for active substances having a skin-safety improvement effect on natural products having excellent safety, and improved skin beauty including a mixture of Panax ginseng extract and Crataegis fructus extract in a specific weight ratio. It was found that the composition for improving skin beauty such as reducing skin wrinkles and increasing skin elasticity, decreasing pore size, brightening skin tone, and improving pigmentation, and completed the present invention.

In order to achieve the above object, the present invention provides a composition for improving skin care comprising a mixture of Panax ginseng extract and Crataegis fructus extract in a 1:10 to 10: 1 weight ratio.

Preferably the composition for improving skin care may comprise a mixture of ginseng extract and hawthorn extract in a weight ratio of 1: 1 to 1: 9, more preferably the ginseng extract and hawthorn extract 1: 3 to 1: 9. It may include a mixture mixed in a weight ratio, and most preferably may include a mixture in which the ginseng extract and the hawthorn extract is mixed in a 1: 3 weight ratio.

The composition for improving skin care includes ginseng and hawthorn extract as an active ingredient.

The process of obtaining a mixture of the ginseng extract and the hawthorn extract in a specific weight part may include a method of extracting ginseng and hawthorn with an extraction solvent.

In one embodiment, a method of obtaining a mixture of ginseng extract and hawthorn extract in a specific weight part comprises the steps of reflux extraction by adding an extraction solvent to the mixture of ginseng and hawthorn; Filtering the extracted reflux extract to obtain a filtrate; It may comprise the step of concentrating the filtrate.

The method of obtaining a mixture of the ginseng extract and the hawthorn extract in a specific weight part may further include obtaining a powder by drying the concentrate obtained by concentrating the filtrate as necessary.

The extractant may be a mixture of ethanol and water.

In another embodiment, the method of obtaining a mixture of ginseng extract and hawthorn extract in a specific weight part to extract reflux of ginseng and hawthorn respectively by adding an extraction solvent, and filtering each reflux extract to obtain a filtrate, and then concentrating. Individual concentrates can also be obtained by mixing.

The method of obtaining a mixture of the ginseng extract and the hawthorn extract in a specific weight part may further include drying the concentrate as necessary to obtain a powder. The concentrate may be dried before the mixing step or the concentrate may be dried after the mixing step.

In addition, the extraction process may further comprise the step of obtaining a fraction having a high content of the active ingredient, if necessary. For example, by dispersing the extract obtained by extraction with the primary extraction solvent in water, and then extracting with an appropriate secondary extraction solvent, it is possible to further increase the active ingredient content in the resulting extract.

The skin care improvement may be one or two or more selected from the group consisting of skin wrinkle reduction, skin elasticity increase, pore size reduction, skin tone brightening and pigmentation improvement.

The skin care improving composition has an excellent tyrosinase inhibitory activity and has an antioxidant effect and a whitening effect. In addition, the composition for improving skin care shows a whitening effect by significantly inhibiting the production of melanin when treated with B16F10 melanoma cells and does not show a change in cell viability and shows excellent safety. In addition, the composition for improving skin care is to increase the expression level of Type-1 Procollagen (HD-1) in human dermal fibroblasts (HDF) and significantly lower the expression level of collagen degrading enzyme MMP-1 Excellent skin beauty improvement and anti-aging effects (reduce skin wrinkles and increase skin elasticity). In addition, the composition for improving skin care has no digestive disorders during taking, no skin problems and no side effects on the human body is safe.

The composition for improving skin beauty is effective in improving skin beauty, such as reducing skin wrinkles and increasing skin elasticity, decreasing pore size, brightening skin tone, and improving pigmentation, as compared to a composition containing only ginseng (Panax ginseng) extract or hawthorn extract alone. Can be significantly improved.

In addition, it has a similar or improved effect of arbutin and kojic acid, which is used as an existing composition for improving skin care. However, unlike kojic acid, it has high safety and there is no problem of carcinogenicity for the development of thyroid cancer.

The skin care improving composition may be a food composition, a pharmaceutical composition or a cosmetic composition.

The pharmaceutical composition may include additives such as pharmaceutically acceptable diluents, binders, disintegrants, lubricants, pH adjusting agents, antioxidants, dissolution aids and the like within the scope of not impairing the effects of the present invention.

The diluent may be sugar, starch, microcrystalline cellulose, lactose (lactose monohydrate), glucose, di-mannitol, alginate, alkaline earth metal salts, clay, polyethylene glycol, anhydrous calcium hydrogen phosphate, or a mixture thereof; Binders are starch, microcrystalline cellulose, highly dispersible silica, mannitol, di-mannitol, sucrose, lactose monohydrate, polyethylene glycol, polyvinylpyrrolidone (povidone), polyvinylpyrrolidone copolymer (copovidone), hypromellose , Hydroxypropyl cellulose, natural gum, synthetic gum, copovidone, gelatin, or a mixture thereof.

The disintegrating agent may be a starch or modified starch such as sodium starch glycolate, corn starch, potato starch or pregelatinized starch; Clay such as bentonite, montmorillonite, or veegum; Celluloses such as microcrystalline cellulose, hydroxypropyl cellulose or carboxymethyl cellulose; Algins such as sodium alginate or alginic acid; Crosslinked celluloses such as croscarmellose sodium; Gums such as guar gum and xanthan gum; Crosslinked polymers such as crosslinked polyvinylpyrrolidone (crospovidone); Effervescent agents such as sodium bicarbonate, citric acid, or mixtures thereof can be used.

The lubricant may be selected from the group consisting of talc, stearic acid, magnesium stearate, calcium stearate, sodium lauryl sulfate, hydrogenated vegetable oil, sodium benzoate, sodium stearyl fumarate, glyceryl behenate, glyceryl monolate, glyceryl monostearate, Stearate, colloidal silicon dioxide, or a mixture thereof may be used.

pH adjusters include acidifying agents such as acetic acid, adipic acid, ascorbic acid, sodium ascorbate, sodium ether, malic acid, succinic acid, tartaric acid, fumaric acid, citric acid (citric acid) and precipitated calcium carbonate, ammonia water, meglumine, carbonate Basic agents, such as sodium, magnesium oxide, magnesium carbonate, sodium citrate, and calcium tribasic phosphate, etc. can be used.

As the antioxidant, dibutylhydroxytoluene, butylated hydroxyanisole, tocopheryl acetate, tocopherol, propyl gallate, sodium hydrogen sulfite, sodium pyrophosphate and the like can be used. In the prior-release compartment of the present invention, Polyoxyethylene sorbitan fatty acid esters such as sodium lauryl sulfate and polysorbate, docusate sodium, poloxamer and the like can be used.

In addition, an enteric polymer, a water-insoluble polymer, a hydrophobic compound, and a hydrophilic polymer may be included to form a delayed-release preparation.

The enteric polymer is insoluble or stable under acidic conditions of less than pH 5, and refers to a polymer that is dissolved or decomposed under specific pH conditions of pH 5 or higher. For example, hypromellose acetate succinate and hypromellose phthalate. (Hydroxypropylmethylcellulose phthalate), hydroxymethylethyl cellulose phthalate, cellulose acetate phthalate, cellulose acetate succinate, cellulose acetate maleate, cellulose benzoate phthalate, cellulose propionate phthalate, methyl cellulose phthalate, carboxymethylethyl cellulose and Enteric cellulose derivatives such as ethyl hydroxyethyl cellulose phthalate and methyl hydroxyethyl cellulose; Styrene-acrylic acid copolymers, methyl acrylate-acrylic acid copolymers, methyl methacrylate acrylic acid copolymers (e.g., acrylics), butyl acrylate-styrene-acrylic acid copolymers, and methyl acrylate-methacrylic acid-octyl acrylate copolymers. The enteric acrylic acid copolymer; Poly (methacrylate methyl methacrylate) copolymer (e.g. Eudragit L, Eudragit S, Evonik, Germany), poly (methacrylate acrylate) copolymer (e.g. Eudragit L100- Enteric polymethacrylate copolymers such as 55); Vinyl acetate-maleic anhydride copolymer, styrene-maleic anhydride copolymer, styrene-maleic acid monoester copolymer, vinylmethyl ether-maleic anhydride copolymer, ethylene-maleic anhydride copolymer, vinylbutyl ether-maleic anhydride copolymer, acrylic Enteric maleic acid copolymers such as ronitrile-methyl methacrylate-maleic anhydride copolymer and butyl styrene-styrene-maleic anhydride copolymer; And enteric polyvinyl derivatives such as polyvinyl alcohol phthalate, polyvinyl acetal phthalate, polyvinyl butyrate phthalate and polyvinyl acetal phthalate.

The water insoluble polymer refers to a polymer that is not soluble in pharmaceutically acceptable water that controls the release of the drug. For example, the water insoluble polymer may be polyvinylacetate (e.g. colicoat SR30D), water insoluble polymethacrylate copolymer [e.g. poly (ethylacrylate-methyl methacrylate) copolymer (e.g. Eudragit NE30D) , Poly (ethylacrylate-methyl methacrylate-trimethylaminoethyl methacrylate) copolymer (e.g., Eudragit RSPO), etc., ethyl cellulose, cellulose ester, cellulose ether, cellulose acylate, cellulose dicylate, Cellulose triacylate, cellulose acetate, cellulose diacetate and cellulose triacetate.

The hydrophobic compound refers to a substance that does not dissolve in pharmaceutically acceptable water that controls the release of the drug. Fatty acids and fatty acid esters such as, for example, glyceryl palmitostearate, glyceryl stearate, glyceryl bihenate, cetyl palmitate, glyceryl monooleate and threric acid; Fatty acid alcohols such as cetostearyl alcohol, cetyl alcohol and stearyl alcohol; Waxes such as carnauba wax, beeswax, and microcrystalline wax; Inorganic materials such as talc, precipitated calcium carbonate, calcium dihydrogen phosphate, zinc oxide, titanium oxide, kaolin, bentonite, montmorillonite, and gum.

The hydrophilic polymer refers to a polymeric material that is dissolved in pharmaceutically acceptable water that controls the release of the drug. Sugars such as, for example, dextrins, polydextrins, dextrans, pectins and pectin derivatives, alginates, polygalacturonic acids, xylans, arabinoxylans, arabinogalactans, starches, hydroxypropylstarches, amylose, and amylopectins ; Cellulose derivatives such as hypromellose, hydroxypropyl cellulose, hydroxymethyl cellulose, hydroxyethyl cellulose, methyl cellulose and carboxymethyl cellulose sodium; Gums such as guar gum, locust bean gum, tragacantha, carrageenan, acacia gum, gum arabic, gellan gum, and xanthan gum; Proteins such as gelatin, casein, and zein; Polyvinyl derivatives such as polyvinyl alcohol, polyvinyl pyrrolidone, and polyvinyl acetal diethylamino acetate; Poly (butyl methacrylate- (2-dimethylaminoethyl) methacrylate-methylmethacrylate) copolymer (e.g. Eudragit E100, Evonik, Germany), poly (ethyl acrylate-methyl methacrylate- Hydrophilic polymethacrylate copolymers such as triethylaminoethyl- methacrylate chloride) copolymers (eg, Eudragit RL, RS, Evonik, Germany); Polyethylene derivatives such as polyethylene glycol, and polyethylene oxide; Carbomer and the like.

In addition, a pharmaceutically acceptable additive may be selected and used in the preparation of the present invention as various additives selected from colorants and fragrances.

In the present invention, the range of the additives is not limited to the use of the above additives, and the above-mentioned additives may be formulated by containing a dose in a normal range by selection.

The pharmaceutical composition according to the present invention may be formulated in the form of oral dosage forms such as pills, powders, granules, tablets, capsules, suspensions, emulsions, syrups and aerosols, external preparations, suppositories, or sterile injectable solutions according to a conventional method. Can be used.

The present invention also provides a method for improving skin care by administering the composition for improving skin care of the present invention to a subject including a mammal. As used herein, the term "administration" means introducing the composition for improving skin care of the present invention to a subject by any suitable method, and the route of administration of the composition for improving skin care of the present invention can reach a target tissue. Administration can be by any general route. Oral administration, intraperitoneal administration, intravenous administration, intramuscular administration, subcutaneous administration, endothelial administration, intranasal administration, intrapulmonary administration, rectal administration, intranasal administration, intraperitoneal administration, intradural administration, but is not limited thereto.

The composition for improving skin care according to the present invention may be administered once or twice a day at regular time intervals.

The dosage of the composition for improving skin care according to the present invention varies depending on the weight, age, sex, health condition, diet, administration time, administration method, excretion rate, and severity of the subject.

It is to be understood that the dosage of the composition for improving skin care of the present invention should be determined according to the activity, sex, time of administration, route of administration, duration and frequency of treatment of the composition for improving skin care of the present invention. It is not intended to limit the scope of the invention in any way.

The composition for improving skin care may have a formulation selected from the group consisting of pills, powders, granules, tablets, capsulants, external preparations, suppositories, and sterile injectable solutions.

The composition for improving skin care of the present invention has a skin wrinkle reduction, skin elasticity increase, pore size reduction, skin tone brightening, pigmentation improvement effect, and thus can be used as a functional cosmetic for improving skin beauty.

The cosmetic composition for improving the beauty of skin may be prepared in any formulation commonly prepared in the cosmetic field, for example, supple cosmetics, astringent cosmetics, nourishing cosmetics, nutrition cream, massage cream, essence, eye cream, eye essence It may have a formulation selected from the group consisting of cleansing cream, cleansing foam, cleansing water, pack, powder, body lotion, body cream, body oil, body essence, makeup base, foundation, hair dye, shampoo, rinse and body cleanser. .

The functional cosmetics for improving skin care may include components commonly used in cosmetic compositions, in addition to a mixture of ginseng and hawthorn extract in a certain amount by weight, for example, fatty substances, organic solvents, solubilizers, concentrates. And gelling agents, emollients, antioxidants, suspending agents, stabilizers, foaming agents, flavoring agents, surfactants, preservatives, water, ionic or nonionic emulsifiers, fillers, metal ion sequestrants and chelating agents, preservatives, vitamins, blockers , Wetting agents, essential oils, dyes, pigments, hydrophilic or lipophilic active agents, lipid vesicles, or any other ingredient commonly used in cosmetics, may contain adjuvant commonly used in the cosmetic field.

Skin care improvement composition of the present invention can be used as a food composition as a health functional food. The term "health functional food" means a food manufactured and processed using raw materials or ingredients having functional properties useful for the human body according to Act No. 6767 of the Health Functional Food Act, and "functionality" refers to the structure of the human body. And ingestion for the purpose of obtaining nutrients for function or for obtaining useful effects in health uses such as physiological actions.

The food composition of the present invention may include a conventional food additives, and the suitability as the "food additives", unless otherwise specified, corresponding items according to the General Regulations and General Test Methods of the Food Additives approved by the Food and Drug Administration It is determined by the standard and the standard.

Examples of the items listed in the "Food Additive Revolution" include, for example, chemical compounds such as ketones, glycine, potassium citrate, nicotinic acid, and cinnamon acid, natural additives such as color pigments, licorice extracts, crystalline cellulose, high color pigments, guar gum, Mixed preparations, such as a sodium L- glutamate preparation, an addition of an alkali, a preservative preparation, and a tar pigment preparation, are mentioned.

Food composition of the present invention can be produced and processed in the form of tablets, capsules, powders, granules, liquid, pills, beverages, tea, pouches and the like for the purpose of improving skin beauty.

For example, the health functional food in the form of tablets is a mixture of ginseng and hawthorn extract in a certain amount by weight ratio, excipients, binders, disintegrants, and other additives granulated in a conventional manner, and then glidants Or the like can be compression molded, or the mixture can be directly compression molded.

In addition, the health functional food in the form of tablets may contain a mating agent and the like, if necessary, may be coated with a suitable coating agent.

Hard capsules of the health functional food in the form of capsules can be prepared by filling a mixture of ginseng and hawthorn extract in a certain amount by weight in a conventional hard capsule, and a mixture with additives such as excipients, or granules or peeled granules thereof. The soft capsule may be prepared by filling a capsule base such as gelatin with a mixture of sucrose and tosa extract and excipients. The soft capsule agent may contain a plasticizer such as glycerin or sorbitol, a colorant, a preservative, and the like, as necessary.

The health functional food in the form of cyclic can be prepared by molding a mixture of ginseng and hawthorn extract in a certain amount by weight, a mixture of excipients, binders, disintegrants, etc. Alternatively, they may be enchanted with starch, talc or any suitable material.

In the health functional food in the form of granules, a mixture of excipients, excipients, binders, disintegrants, and the like, mixed with ginseng and hawthorn extract in a certain amount by weight, can be prepared in granules by a suitable method. It may contain. For the health functional food in the form of granules, No. 12 (1680 μm), No. 14 (1410 μm) and No. 45 (350 μm) are used for the next particle size test. Less than 5.0% and passing through the 45 can be less than 15.0% of the total amount.

The definitions of the above excipients, binders, disintegrants, lubricants, mating agents, flavoring agents, and the like are described in documents known in the art and include the same or similar functions (Korean Pharmacopoeia, College of Pharmacy, 5th ed., P. 33-48, 1989).

The composition for improving skin care according to the present invention is safe for the human body while showing excellent effects such as reducing skin wrinkles, increasing skin elasticity, decreasing pore size, brightening skin tone, improving pigmentation, and improving skin beauty foods, medicines and It can be safely applied to cosmetic compositions.

1 is a circular chart showing the results of the panel test for the wrinkle reduction effect, skin elasticity increase effect and pore size reduction effect of the ring containing the ginseng and hawthorn mixed extract of Example 2 according to Experimental Example 1 of the present invention.
Figure 2 is a circular chart showing the results of the panel test for the lightening effect, pigmentation improvement effect and sebum reduction effect of the skin tone of the ring containing the ginseng and hawthorn mixed extract of Example 2 according to Experimental Example 1 of the present invention.
Figure 3 is a circular chart showing the results of the panel test for the digestive disorders and the skin problems when taking the pill containing the ginseng and hawthorn mixed extract of Example 2 according to Experimental Example 1 of the present invention.
Figure 4 is a graph showing the results of measuring the tyrosinase inhibitory activity of the compositions of Examples 1-1 to 1-3 and the compositions of Comparative Examples 1 to 4 in accordance with Experimental Example 1 of the present invention. In FIG. 4, the concentrations of ginseng, hawthorn, blending ratio 1, blending ratio 2, blending ratio 3, Arbutin and Kojic acid on the x-axis are ginseng extract, hawthorn extract, ginseng and hawthorn mixed extract of Example 1, Example 2 Ginseng and Sansa mixed extract of Example 3, Ginseng and Sansa mixed extract of Example 3, Arbutin of Comparative Example 3, Kojic acid concentration of Comparative Example 4 means (μg / ㎖), the y-axis shows the tyrosinase inhibition rate (Inhibition Rate,%) .
5 is related to the effect on the cell viability of the compositions of Examples 1-1 to 1-2 and the compositions of Comparative Examples 1, 2 and 4 according to Experimental Example 3 of the present invention and the effect on the intracellular melanin content change It is a graph showing the experimental results. In FIG. 5, the control of the x-axis is the untreated control, (+) is the alpha-melanin stimulating hormone (alpha-MSH) added group, Kojic Acid is treated with kojic acid, ginseng is treated with ginseng extract, Sansa extract treatment group, compounding ratio 1 is a composition treatment group of Example 1-1 compounding ratio 2 means a composition treatment group of Example 1-2, the y-axis is expressed as a percentage (% of control) of the control.
6 is a type 1 procollagen of the composition of Example 1-1 (combination ratio 1) and the composition of Comparative Example 1 (ginseng extract), 2 (sansa extract) and 4 (Kojic Acid) according to Experimental Example 4 of the present invention. (Type-1 Procollagen) and Western blot results showing changes in protein expression levels of MMP-1. In FIG. 6, β-actin, a house keeping gene, expressed at the same level in most cells was used as a reference to show whether the same amount of protein was analyzed.

Hereinafter, the present invention will be described in more detail with reference to the following Examples and Experimental Examples. These Examples and Experimental Examples are only for illustrating the present invention, and the scope of the present invention is not limited to the following Examples and Experimental Examples.

Example 1 Preparation of Ginseng and Sansa Mixed Extract

Domestic ginseng and domestic acid sand obtained from Kumgang Pharmaceutical Co., Ltd. were ground to 20-40 mesh, and the ginseng pulverized product and the acid sand pulverized powder were mixed at the ratio of Table 1 to obtain a mixture of ginseng pulverized product and acid sand pulverized product.

Ginseng Grind (g) Sansa grinding (g) Example 1-1 100 300 Examples 1-2 100 900 Example 1-3 100 100

The mixtures of the ginseng pulverized product and the pulverized pulverized sand were respectively extracted by refluxing at 70 ° C. for 4 hours after adding 10 times 70 volume% ethanol (EtOH). After extraction, the resultant was filtered using a filter paper (4 μm, watman), and then concentrated under reduced pressure for 6 to 12 hours at 45 ° C. using a vacuum condenser (product name: Coolace CCA-1100, manufacturer: EYELA). After removing ethanol (EtOH) to obtain a concentrated solution to prepare a ginseng and mountain sand mixed extract of Examples 1-1 to 1-3.

Example  2. Preparation of Rings Containing Ginseng and Sansa Mixed Extract

The ginseng and mountain sand mixed extract (mixing ratio of ginseng and acid sand 1: 3) of Example 1-1 was concentrated to obtain 5 kg of concentrate and 25 Bx (Brix). Spray drying was performed using this. When spray drying, spray drying was carried out using a 2ton spray dryer (Korea Medi Co., Ltd.), and 1.25kg maltodextrin (DE 12, Into Food Co., Ltd.) was mixed and spray drying was performed at an input temperature of 170 ° C. and a discharge temperature of 90 ° C. It proceeded and recovered a total of 1 kg of powder. The spray-dried powder itself is impossible to prepare the pill, so select the crystalline cellulose (Sinwon Trading Co.) as a water-insoluble excipient, and by concentration of up to 10%, 20%, 30% (wherein the concentration is a spray-dried powder It was confirmed that the dough and refilling in the 30% addition group as a result of the dough experiment with). After kneading, it was prepared as a summoning agent having a diameter of 2.5 mm by using a recall machine. After the preparation was dried for at least 12 hours in a dry condition of less than 60 ℃ to dry up to 10% or less moisture content to prepare a ring containing the ginseng and mountain sand mixed extract of Example 2.

Comparative Example 1. Preparation of Ginseng Extract

Ginseng extract was prepared in substantially the same manner as in Example 1 except that ginseng grinds were used instead of a mixture of ginseng grinds and mountain sand grits.

Comparative example  2. Preparation of Sansa Extract

The ginseng extract was prepared in substantially the same manner as in Example 1 except that the pulverized pulverized pulverized pulverulent was used instead of the mixture of the ginseng pulverized and the pulverized pulverized pulverulent.

Comparative example  3. Preparation of Arbutin

Arbutin (product name: Arbutin) manufactured by Sigma was purchased from Sigma-Aldrich Korea to prepare arbutin.

Comparative example  4. Preparation of Kojic Acid

Kojic acid manufactured by Sigma (product name: Kojic acid) was purchased from Sigma-Aldrich Korea to prepare kojic acid.

Experimental Example 1. Confirmation of Skin Beauty Improvement Effect-Panel Test

Using a ring containing the ginseng and Sansa mixed extract of Example 2 was carried out a panel test for the effect of improving wrinkles and skin care.

Specifically, 20 healthy women and males up to age 50 to take the pill prepared in Example 2 three times a day for two weeks. After 2 weeks (i) decreased wrinkles and increased skin elasticity, (ii) reduced pore size, (iii) improved skin tone and improved pigmentation, (iv) reduced sebum, and (v) digestion while taking Disability and (vi) skin problems when taking 'yes', 'usually', 'not' compared to before taking. Was determined in three steps, and the results are shown in FIGS. 1, 2, and 3.

As shown in the results of Figure 1, when taking the pill containing the ginseng and hawthorn mixed extract of the present invention, it can be seen that the skin wrinkles are reduced, the skin elasticity is increased, the size of the pores is also reduced.

As shown in the results of Figure 2, when taking the pill containing the ginseng and hawthorn mixed extract of the present invention, the skin tone was brightened, the pigmentation was improved, it was confirmed that the sebum is reduced.

As shown in the results of Figure 3, most of the panel when taking the pill containing the ginseng and hawthorn mixed extract of the present invention, there is no digestive disorder during taking, there is no skin trouble ring containing the ginseng and hawthorn mixed extract of the present invention the human body There was no side effect and it was confirmed that it was safe.

Experimental Example  2. Confirm antioxidant and whitening effect- Tyrosinase  Inhibitory activity

Mushroom-derived tyrosinase inhibitory activity involved in melanin biosynthesis and oxidation by modifying the activity assay described in Ishihara Y et al. J. Antibiot (Tokyo) 44 (1), p25-32, 1991. Was measured.

Specifically, extracts prepared in Examples 1, 2 and Comparative Examples 1 to 4 in 50 µl of 3 mg / ml tyrosine solution (dissolved in 0.1 M phosphate buffer, pH 6.8) and 1 ml of 50% by volume methanol solution were prepared. Each was added to prepare a sample for each concentration. The sample for each concentration is 100 ㎍ / ㎖ ginseng extract of Comparative Example 1 (see ginseng of Figure 4), 100 ㎍ / ㎖ hawthorn extract (see the hawthorn in Figure 4), 50 ㎍ mixed extract of ginseng and hawthorn of Example 1 / Ml and 100µg / ml (see blending ratio 1 of Figure 4), ginseng and mountain sand mixed extract of Example 2 50µg / ml and 100µg / ml (see blending ratio 2 of Figure 4), ginseng and mountain sand of Example 3 50 μg / ml and 100 μg / ml of the mixed extract (see FIG. 4 in compounding ratio 3), 100 μg / ml of arbutin of Comparative Example 3 (see Arbutin in FIG. 4) and 100 μg / ml of kojic acid of Comparative Example 4 (of FIG. 4). Kojic acid).

50 μl of each sample was placed in a 96-well plate, respectively. 50 μl of mushroom extract tyrosinase (Sigma, dissolved in 200 Unit / ml, 0.1 M phosphate buffer, pH 6.8) was added. Then, after incubating for 10 minutes at 37 ℃, the amount of dopachrome produced was measured for absorbance at 475nm using a spectrophotometer (Precision microplate reader; Molecular Devices, VersaMax). The experiment was repeated three times. Dopachrome is an intermediate of melanin production and may have a whitening effect when dopachrome production is inhibited.

Tyrosinase inhibitory activity was calculated according to Equation 1 according to Matsuda et al. (Matsuda H et al. Biol. Pharm. Bull. 19 (1), p153-156, 1996) using the sample without the sample as a control. The results are shown in FIG. 4.

[Formula 1]

Tyrosinase Inhibitory Activity (%) = {(Control OD ₄₇₅ -Sample OD ₄₇₅ ) / Control OD ₄₇₅ } X 100

In Equation 1, OD ₄₇₅ represents an optical density measurement at ₄₇₅ nm.

As shown in Figure 4, the mixture of the ginseng and hawthorn extract of the present invention in a certain amount by weight ratio has a tyrosinase inhibitory activity significantly superior to the ginseng extract or hawthorn extract of the same concentration. In addition, even when only 50% of the concentration of ginseng extract or hawthorn extract was mixed with a mixture of ginseng and hawthorn extract in a certain amount by weight ratio, it showed that the tyrosinase inhibitory activity was comparable to that of ginseng extract or hawthorn extract. have.

Therefore, it can be seen that the composition comprising a mixture of ginseng and hawthorn extract according to the present invention in a certain amount by weight ratio has a significantly superior antioxidant and whitening effect than the composition comprising a single extract of ginseng and hawthorn. In addition, it can be seen that the composition comprising a mixture of ginseng and hawthorn extract of the present invention mixed in a certain amount by weight ratio may exhibit an antioxidant effect and a whitening effect by showing tyrosinase inhibitory activity in a concentration-dependent manner.

Experimental Example  3. Check the whitening effect-melanin content measurement

B16F10 mouse-derived B16F10 murine melanoma cell line (ATCC CRL-9475) containing 100 units / ml antibacterial-antifungal solution containing penicillin and streptomycin (PAA, Canada) ) And DMEM (PAA, Canada) medium with 10% FBS (PAA, Canada) were added and cultured in a 37 ° C., 5% CO ₂ incubator. Thereafter, after 2-3 passages a week, the cells were inoculated with 1 × 10 ⁴ cells / well in 24-well plates and incubated for 24 hours. To the medium of the 24-well plate was added alpha-melanin stimulating hormone (alpha-MSH), which is known to promote melanogenesis. 990 μl of the culture solution per well was changed daily, and 100 μg / ml of the ginseng and hawthorn mixed extract of Example 1 (see FIG. 5, mixture ratio 1), and 100 μg / ml of the ginseng and hawthorn mixed extract of Example 2 (the combination ratio of FIG. 5). 2 μg) and 100 μg / ml kojic acid (see Kojic acid in FIG. 4) of Comparative Example 4 were each added, and further cultured for 1 day.

Thereafter, after removing the medium from the cultured cells, the cells were recovered and centrifuged to obtain cell pellets. After addition of 1N sodium hydroxide solution containing 10% DMSO (dimethyl sulfoxide), incubated at 60 ° C. for 2 hours to dissolve melanin, and then at 400 to 405 nm, a precision microplate reader (Molecular Devices, VersaMax). Absorbance was measured using, and melanin content was measured. The results are shown in FIG. 5.

As shown in Figure 5, the mixture of the ginseng and mountain sand extract of the present invention in a certain amount by weight ratio may reduce the melanin content compared to kojic acid, ginseng extract alone or the acid extract alone in the same concentration.

Therefore, it can be seen that the composition comprising a mixture of ginseng and hawthorn extract of the present invention mixed in a certain amount by weight may reduce the melanin content and have a whitening effect.

Experimental Example 4. Confirmation of cytotoxicity-measurement of cell viability

After removing the medium from the cells cultured in Example 3, the cells were washed with 10 mM phosphate buffer solution (PBS, Bio World Co., pH 7.4), and then crystal violet staining solution (Crystal violet (HT90132, Sigma-Aldrich) Korea) was incubated at room temperature for 5 minutes by adding 200 μl, and washed twice with water, shaken at room temperature for 20 minutes with the addition of 1 ml of ethanol, and the absorbance was measured at 590 nm using a spectrophotometer. Survival was measured and the results are shown in FIG. 5.

As shown in Figure 5, the mixture of ginseng and hawthorn extract of the present invention in a certain amount by weight ratio can be confirmed that the low cytotoxicity can be used as an excellent skin whitening composition.

Experimental Example  5. Identification of anti-aging and whitening effects- Type -One Procollagen Creation degree  And MMP -1 inhibition degree measurement

Human fibroblasts (Catalog No: MC1213, MCTT, Seoul, Korea) were placed in a 60 mm cell culture dish with 3 ml of culture solution and about 1 X 10 ⁵ Cells were seeded at the concentration of cells / culture dishes and then incubated for 24 hours in a 37 ° C., 5% CO ₂ environment. Subsequently, after irradiating ultraviolet B at 20 mJ / cm 2, the samples prepared in Example 1, Example 2 and Comparative Examples 1 to 4 were replaced with a medium to which 100 µg / ml was added, respectively, and cultured for 2 days.

After 2 days of culture, the cells were harvested to separate proteins, and Western blot method was used for type-1 procollagen and matrix metalloproteinase-1. -1; MMP-1) protein expression level was confirmed. Western blot was performed in the following manner. The cultured cells were washed with ice-cold PBS (phosphate buffered saline), followed by 40 μl of lysis buffer (50 mM HEPES, pH 7.0, 250 mM NaCl, 5 mM EDTA, 0.1% Nonidet P-40, 1 mM phenylmethylsulphate). The supernatant was extracted by centrifugation after extracting the protein using ronyl fluoride (phenylmethylsulfonyl fluoride), 0.5mM dithiothreitol, 5mM NaF, 0.5mM Na orthovanadate (Na orthovanadate). The supernatant was quantified for protein concentration using the Bio-Rad DC Protein Assay Kit (500-0111-MSDS, Bio-Rad) reagent, and then subjected to 10% SDS-PAGE (50 μg / lane of protein). Transfer was performed with a nitrocellulose membrane. The membrane was blocked with 5% skim milk for 1 hour and blocked with type 1 procollagen (ab64409, Abcam, 1: 1000), matrix metalloproteinase-1 (ab38929, Abcam). , 1: 1000) The antibody was reacted at 4 ° C. overnight and then washed three times at 15 minute intervals with Tris buffered saline (10 mM tris-HCl, pH 7.4, 150 mM NaCl, 0.1% Tween 20). . Rabbit (ab6721, Abcam) and rat (ab97057, Abcam) secondary antibodies diluted at a ratio of 1: 5000 were reacted at room temperature for 2 hours. Again washed three times with TBST buffer for 15 minutes and confirmed by ECL (Intron Inc.) western blotting system. The results are shown in FIG.

As shown in Figure 6, the mixture of the ginseng and hawthorn extract of the present invention in a certain amount of weight ratio increases the type 1 procollagen expression in human dermal fibroblasts and significantly lowers the MMP-1 expression, a collagen degrading enzyme As a result, it was confirmed that the anti-aging effect (reduce skin wrinkles and increase skin elasticity) and the whitening effect is excellent.

Claims (6)

Ginseng (Panax ginseng) extract and Sansa (Crataegis fructus) extract comprising a mixture of 1:10 to 10: 1 by weight ratio composition for improving skin care. According to claim 1, wherein the skin care improvement is one or more of the composition for skin care personality selected from the group consisting of reduced skin wrinkles, increased skin elasticity, reduced pore size, lighter skin tone and improved pigmentation. According to claim 1, wherein the composition for improving skin care is a composition for improving skin care is a food composition, a pharmaceutical composition or a cosmetic composition. According to claim 3, wherein the composition for improving skin care is a composition for improving skin care, which is a pharmaceutical composition having a formulation selected from the group consisting of pills, powders, granules, tablets, capsulants, external preparations, suppositories, and sterile injectable solutions. According to claim 3, wherein the composition for improving skin care is a softening longevity, astringent makeup, nourishing cosmetics, nutrition cream, massage cream, essence, eye cream, eye essence, cleansing cream, cleansing foam, cleansing water, pack, powder, body A lotion, body cream, body oil, body essence, make-up base, foundation, hair dye, shampoo, rinse and body cleanser composition for improving skin care, a composition having a formulation selected from the group. The food composition according to claim 3, which is selected from the group consisting of tablets, capsules, powders, granules, liquids, pills, beverages, teas and pouches.

Images